Torres HA, Mahale P, Miller ED, Oo TH, Frenette C, Kaseb AO. Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. World J Hepatol 2013; 5(6): 332-335 [PMID: 23805358 DOI: 10.4254/wjh.v5.i6.332]
Corresponding Author of This Article
Harrys A Torres, MD, FACP, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States. htorres@mdanderson.org
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Jun 27, 2013; 5(6): 332-335 Published online Jun 27, 2013. doi: 10.4254/wjh.v5.i6.332
Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma
Harrys A Torres, Parag Mahale, Ethan D Miller, Thein H Oo, Catherine Frenette, Ahmed O Kaseb
Harrys A Torres, Parag Mahale, Departments of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
Ethan D Miller, Departments of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
Thein H Oo, Section of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
Catherine Frenette, Liver Transplantation, Weill Cornell Medical College, The Methodist Hospital, Houston, TX 77030, United States
Ahmed O Kaseb, Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
Author contributions: Torres HA, Miller ED, Oo TH, Frenette C and Kaseb AO provided care to the patient and designed the study; Mahale P collected the data; Torres HA, Miller ED, Oo TH, Frenette C and Kaseb AO analyzed and interpreted the data; Torres HA and Mahale P drafted the manuscript; Torres HA, Mahale P, Miller ED, Oo TH, Frenette C and Kaseb AO provided critical revision of the manuscript for important intellectual content.
Correspondence to: Harrys A Torres, MD, FACP, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States. htorres@mdanderson.org
Telephone: +1-713-7926830 Fax: +1-713-746839
Received: March 2, 2013 Revised: May 1, 2013 Accepted: May 17, 2013 Published online: June 27, 2013 Processing time: 117 Days and 11.5 Hours
Abstract
The use of direct-acting antiviral agents (e.g., telaprevir, boceprevir) has improved response rates in patients with hepatitis C virus (HCV) genotype 1 infections. Substantial number of drug-drug interactions are anticipated with the use of telaprevir, a cytochrome P450 3A and P-glycoprotein substrate and inhibitor. Herein we describe a patient with HCV-associated hepatocellular carcinoma treated simultaneously with a telaprevir-containing regimen and localized chemotherapy (transcatheter arterial chemoembolization) with doxorubicin. No clinically relevant interactions or adverse events developed while on antiviral therapy.
Core tip: This case suggests that therapy for chronic hepatitis C virus (HCV) infection may be given simultaneously with localized chemotherapy in patients with hepatocellular carcinoma (HCC). The use of telaprevir has improved response rates in patients with HCV genotype 1 infections. Substantial number of drug-drug interactions are anticipated with the use of telaprevir, a cytochrome P450 3A and P-glycoprotein substrate and inhibitor. Herein, we describe a patient with HCV-associated HCC treated simultaneously with a telaprevir-containing regimen and localized chemotherapy (transcatheter arterial chemoembolization). No clinically relevant interactions or adverse events developed while on antiviral therapy.
